Skip to main content
Premium Trial:

Request an Annual Quote

Deepcell: Bruce Wu, Dan Douglas

Bruce Wu has been appointed as chief legal officer and Dan Douglas as VP of finance at single-cell analysis firm Deepcell. Wu previously held senior legal executive roles at General Inception, Sestina Bio, and Nutcracker Therapeutics. Before that, he held intellectual property-focused roles at Illumina and HP, and he was an IP attorney at Foley & Lardner and Pillsbury Winthrop Shaw Pittman. He holds a JD from Georgetown University, as well as MS and PhD degrees in engineering from the Massachusetts Institute of Technology and a BASc in engineering from the University of Toronto. Douglas previously held finance leadership roles at Slingshot Biosciences and Guardant Health, as well as financial analysis roles at HotChalk, CenturyLink, and the General Services Administration. He has an MBA from the University of Denver and a BA from Palm Beach Atlantic University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.